17 September 2021
(“IQ-AI” or the “Company”)
IB Software Chosen for Quantitative Accuracy and Automation
IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF) today announced the sale of multiple licenses of Imaging Biometrics (IB) software for the automated generation of quantitative perfusion maps. The sales consist of renewal licenses for established clients and a new installation of IB Clinic at the Eastern Alabama Medical Center (EAMC).
IB Clinic – Container edition is a fully automated processing pipeline for all IB Software modules, including IB Neuro, IB Delta T1 maps, IB DCE, and IB Diffusion. Ever since it has been made available, the clinical adoption of the container edition has grown steadily with hospitals and imaging centers of all sizes. Of value to clinicians is the automated generation of IB’s quantitative output maps and, specifically, IB Neuro’s quantitative relative cerebral blood volume (rCBV) maps; a magnetic resonance imaging (MRI) method for evaluating brain tumors. The automated workflow frees valuable resources, such as neuro radiologists and MR Technologists while, at the same time, provides unique information shown useful in the diagnosis and treatment optimization of brain tumor patients.
It is the quantitative capabilities of IB software that allows for a standardized imaging protocol across sites and platforms. For instance, a patient scanned at one site on a given MR scanner platform can have a follow-up scan performed on a different MR scanner and the data, if processed with IB Neuro, will be directly comparable and enable accurate longitudinal assessment. Quantitatively assessing how a tumor is changing over time is critical for both clinicians and their patients.
Added Dr. Matthew Dobbs, MD, a radiologist at EAMC, “We have been using IB quantitative perfusion imaging for over a year at our main cancer center and the information has been invaluable to us in determining brain tumor treatment planning and follow-up. When the radiation oncologists at one of our hospitals requested MR perfusion, we immediately recommended purchasing IB software based on our positive experiences.”
“While the pandemic negatively impacted sales earlier this year, we are grateful for the rapid return of sales activity as well as trial evaluations of our software,” said Michael Schmainda, CEO of IB.
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
About Imaging Biometrics, LLC
Imaging Biometrics®, a subsidiary of IQ-AI Limited (LON:IQAI) (OTCQB: IQAIF), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB’s advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com.